TCON (TRACON Pharmaceuticals) Total Assets : $7.40 Mil (As of Jun. 2024)

View and export this data going back to 2015. Start your Free Trial

What is TRACON Pharmaceuticals Total Assets?

TRACON Pharmaceuticals's Total Assets for the quarter that ended in Jun. 2024 was $7.40 Mil.

During the past 12 months, TRACON Pharmaceuticals's average Total Assets Growth Rate was -89.20% per year. During the past 3 years, the average Total Assets Growth Rate was 5.60% per year. During the past 5 years, the average Total Assets Growth Rate was 3.40% per year. During the past 10 years, the average Total Assets Growth Rate was 11.50% per year.

During the past 12 years, TRACON Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 109.60%. The lowest was -19.30%. And the median was 6.00%.

Total Assets is connected with ROA %. TRACON Pharmaceuticals's annualized ROA % for the quarter that ended in Jun. 2024 was -135.55%. Total Assets is also linked to Revenue through Asset Turnover. TRACON Pharmaceuticals's Asset Turnover for the quarter that ended in Jun. 2024 was 0.01.

TRACON Pharmaceuticals Total Assets Historical Data

The historical data trend for TRACON Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TRACON Pharmaceuticals Total Assets Chart

TRACON Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

18.12

37.44

26.56

19.47

10.11

TRACON Pharmaceuticals Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Total Assets	Get a 7-Day Free Trial															12.19	9.41	10.11	9.36	7.40

TRACON Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

TRACON Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	-0.809	+	10.914
	=	10.11

TRACON Pharmaceuticals's Total Assets for the quarter that ended in Jun. 2024 is calculated as

Total Assets	=	Total Equity (Q: Jun. 2024 )	+	Total Liabilities (Q: Jun. 2024 )
	=	-3.089	+	10.489
	=	7.40

TRACON Pharmaceuticals (OTCPK:TCON) Total Assets Explanation

Total Assets is connected with ROA %.

TRACON Pharmaceuticals's annualized ROA % for the quarter that ended in Jun. 2024 is

ROA %	=	Net Income (Q: Jun. 2024 )	/	( (Total Assets (Q: Mar. 2024 )	+	Total Assets (Q: Jun. 2024 ))	/ count )
	=	-11.356	/	( (9.355	+	7.4)	/ 2 )
	=	-11.356	/	8.3775
	=	-135.55 %

Note: The Net Income data used here is four times the quarterly (Jun. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

TRACON Pharmaceuticals's Asset Turnover for the quarter that ended in Jun. 2024 is

	Asset Turnover
=	Revenue (Q: Jun. 2024 )	/	( (Total Assets (Q: Mar. 2024 )	+	Total Assets (Q: Jun. 2024 ))	/ count )
=	0.055	/	( (9.355	+	7.4)	/ 2 )
=	0.055	/	8.3775
=	0.01

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

TRACON Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of TRACON Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

TRACON Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TRACON Pharmaceuticals Inc (OTCPK:TCON) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

4350 La Jolla Village Drive, Suite 800, San Diego, CA, USA, 92122

Website

https://www.traconpharma.com

TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States. The company's drug candidate includes Envafolimab, TRC102, TRC253, and Bispecific Antibodies.

Executives

Opaleye Management Inc.	10 percent owner	ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Charles Theuer	director, officer: President and CEO	C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Bonne J. Adams	officer: Chief Operating Officer	C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Scott B. Brown	officer: Chief Accounting Officer (PAO)	C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
William R Larue	director	C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, SUITE 700, SAN DIEGO CA 92122
Carol C. Lam	director	C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, STE 800, SAN DIEGO CA 92122
Saundra L Pelletier	director	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Lisa Johnson-pratt	director	C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Ikarian Healthcare Master Fund, L.p.	10 percent owner, other: Member of 10% Group	100 CRESCENT COURT, SUITE 1620, DALLAS TX 75201
Mark C Wiggins	officer: Chief Business Officer	12671 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA 92130
Neil Shahrestani	10 percent owner, other: Member of 10% Group	12806 WINDING CREEK DRIVE, FRISCO TX 75035
Ikarian Healthcare Fund Gp, L.p.	10 percent owner, other: Member of 10% Group	100 CRESCENT COURT, SUITE1620, DALLAS TX 75201
Chart Westcott Living Trust	10 percent owner, other: Member of 10% Group	100 CRESCENT COURT, SUITE1620, DALLAS TX 75201
Ikarian Capital, Llc	10 percent owner, other: Member of 10% Group	100 CRESCENT COURT, SUITE 1620, DALLAS TX 75201
Puissance Cross-border Opportunities V Llc	10 percent owner	950 THIRD AVENUE, 25TH FL, NEW YORK NY 10022